Home Compare COFB.BR vs RPRX
Stock Comparison · Structural lead, mixed market

Cofinimmo vs Royalty Pharma: Which Stock Looks Stronger in 2026?

Royalty Pharma holds the cleaner structural position, with the lead spread across profitability and growth. Cofinimmo still has the edge on valuation, which keeps the comparison from looking entirely one-sided. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (COFB.BR: STOXX 600, RPRX: Russell 1000).

Updated 2026-05-17

The clearest separation starts in profitability, but growth adds another real layer to the result. Royalty Pharma plc leads by 17 points on the overall comparison score.

Trajectory Similarity
0.69
Moderately similar
Peer-set rank: #46
within Cofinimmo SA's functional peer set

This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.

The pair shares a valid long-term profile match, but the trajectories are not especially close.

Most of the shared profile comes through investment intensity and revenue stability.

Similarity drivers
investment intensityrevenue stability
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
COFB.BR
Cofinimmo SA
49
Peer-Score
Signal qualitylow
Peer basis: STOXX 600
vs
RPRX
Royalty Pharma plc
66
Peer-Score
Signal qualitylow
Peer basis: Russell 1000

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: COFB.BR vs RPRX Profitability 48 85 Stability 32 57 Valuation 74 58 Growth 30 59 COFB.BR RPRX
Gap Ranking
#1 Profitability +37
#2 Growth +29
#3 Stability +25
#4 Valuation +16
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for COFB.BR and RPRX Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer COFB.BRRPRX Relative valuation Structural strength

Royalty Pharma plc is cheaper, but Cofinimmo SA is still stronger.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Entry today — historical context

Where COFB.BR and RPRX each sit in their own 5-year price and valuation history.

BASED ON 5-YEAR HISTORY COFB.BR Elevated · near norm 0th 50th 100th 28 pct gap RPRX Elevated · above norm 0th 50th 100th 71st 99th
Today COFB.BR sits in the upper-middle of its own 5-year history (71st percentile), while RPRX sits higher in its own history (99th). Within each stock's own 5-year context, COFB.BR is at a historically more favourable entry position than RPRX. This reflects entry timing, not which company is structurally stronger — peer-relative analysis is a separate question addressed above.

Describes historical entry positioning only. Descriptive — not investment advice.

Relative Position vs Comparable Companies
Profitability
Both rank well on profitability, but Royalty Pharma plc still holds a clear edge.
Growth
On growth, Royalty Pharma plc is positioned higher in the group, while Cofinimmo SA is closer to the middle.
Profitability — Dominant Gap
COFB.BR
48
RPRX
85
Gap+37in favour of RPRX

The profitability lead is mainly driven by a 18.7-point operating margin advantage.

What keeps the gap from being one-sided

Absolute pricing still looks more supportive for Cofinimmo, with a trailing P/E that is 12.1 turns lower there.

What this means for the comparison

The lead is built on both profitability and growth — though valuation still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the COFB.BR vs RPRX comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar profitability-and-growth comparisons

Explore how COFB.BR and RPRX each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.